Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Oystein Bruserud

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Physiology

Anatomy

Procedures

Hematopoietic Stem Cell Transplantation

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
17
Gjertsen, Bjørn Tore
12
Ulvestad, Elling
11
Foss, Brynjar
10
Nesthus, Ingerid
6
Abrahamsen, Jenny Foss
6
Bergheim, J
5
Kalland, Karl-Henning
5
Hervig, Tor
5
Ryningen, Anita
5
Oyan, Anne Margrete
4
Anensen, Nina
4
Jonassen, Inge
4
Bø, Trond Hellem
4
Ersvaer, Elisabeth
3
Frostad, S

Sign-in to see all Coauthors

Publications

TOP 3
Reikvam H; Ersvaer E; Bruserud O
Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia.
Foss Brynjar; Hervig Tor; Bruserud Oystein
Connexins are active participants of hematopoietic stem cell regulation.
Ryningen Anita; Stapnes Camilla; Lassalle Philippe; Corbascio Matthias; Gjertsen Bjørn-Tore; Bruserud Oystein
A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Oystein Bruserud (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Reikvam H; Ersvaer E; Bruserud O
Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia.
Current cancer drug targets 2009;9(6):761-76.
2009: Foss Brynjar; Hervig Tor; Bruserud Oystein
Connexins are active participants of hematopoietic stem cell regulation.
Stem cells and development 2009;18(6):807-12.
2009: Ryningen Anita; Stapnes Camilla; Lassalle Philippe; Corbascio Matthias; Gjertsen Bjørn-Tore; Bruserud Oystein
A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid.
Leukemia research 2009;33(6):779-87.
2009: Stapnes Camilla; Gjertsen Bjørn Tore; Reikvam Håkon; Bruserud Øystein
Targeted therapy in acute myeloid leukaemia: current status and future directions.
Expert opinion on investigational drugs 2009;18(4):433-55.
2009: Reikvam Håkon; Blom Unni Sandaker; Kristoffersen Einar; Liseth Knut; Bruserud Oystein; Hervig Tor
[Granulocyte transfusion]
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række 2009;129(5):416-9.
2009: Øyan Anne Margrete; Anensen Nina; Bø Trond Hellem; Stordrange Laila; Jonassen Inge; Bruserud Øystein; Kalland Karl-Henning; Gjertsen Bjørn Tore
Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia.
BMC cancer 2009;9():77.
2008: Olsnes Astrid Marta; Ersvaer Elisabeth; Ryningen Anita; Bruserud Oystein
Circulating T cells derived from acute leukemia patients with severe therapy-induced cytopenia express a wide range of chemokine receptors.
Hematology (Amsterdam, Netherlands) 2008;13(6):329-32.
2008: Akkök Cigdem A; Liseth Knut; Nesthus Ingerid; Løkeland Turid; Tefre Kari; Bruserud Oystein; Abrahamsen Jenny F
Autologous peripheral blood progenitor cells cryopreserved with 5 and 10 percent dimethyl sulfoxide alone give comparable hematopoietic reconstitution after transplantation.
Transfusion 2008;48(5):877-83.
2008: Foss Brynjar; Bruserud Oystein; Hervig Tor
Platelet-released supernatants enhance hematopoietic stem cell proliferation in vitro.
Platelets 2008;19(2):155-9.
2008: Foss Brynjar; Bruserud Oystein
Platelet functions and clinical effects in acute myelogenous leukemia.
Thrombosis and haemostasis 2008;99(1):27-37.
2007: Oyan Anne Margrete; Bø Trond Hellem; Jonassen Inge; Ulvestad Elling; Tore Gjertsen Bjørn; Bruserud Oystein; Kalland Karl-Henning
Global gene expression in classification, pathogenetic understanding and identification of therapeutic targets in acute myeloid leukemia.
Current pharmaceutical biotechnology 2007;8(6):344-54.
2007: Ersvaer Elisabeth; Zhang Jian-Ying; McCormack Emmet; Olsnes Astrid; Anensen Nina; Tan Eng M; Gjertsen Bjørn Tore; Bruserud Oystein
Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients.
European journal of haematology 2007;79(3):210-25.
2007: Petersen Kjell; Oyan Anne Margrete; Rostad Kari; Olsen Sue; Bø Trond Hellem; Salvesen Helga B; Gjertsen Bjørn Tore; Bruserud Oystein; Halvorsen Ole Johan; Akslen Lars Andreas; Steen Vidar M; Jonassen Inge; Kalland Karl-Henning
Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization.
Analytical biochemistry 2007;366(1):46-58.
2007: Stapnes Camilla; Døskeland Anne P; Hatfield Kimberley; Ersvaer Elisabeth; Ryningen Anita; Lorens James B; Gjertsen Bjørn Tore; Bruserud Oystein
The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells.
British journal of haematology 2007;136(6):814-28.
2007: Irish Jonathan M; Anensen Nina; Hovland Randi; Skavland Jørn; Børresen-Dale Anne-Lise; Bruserud Oystein; Nolan Garry P; Gjertsen Bjørn T
Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53.
Blood 2007;109(6):2589-96.
2006: Hatfield Kimberley; Ryningen Anita; Corbascio Matthias; Bruserud Oystein
Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts.
International journal of cancer. Journal international du cancer 2006;119(10):2313-21.
2006: Anensen Nina; Oyan Anne Margrete; Bourdon Jean-Christophe; Kalland Karl Henning; Bruserud Oystein; Gjertsen Bjorn Tore
A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(13):3985-92.
2006: Apelseth Torunn O; Hervig Tor A; Wentzel-Larsen Tore; Bruserud Oystein
Cytokine accumulation in photochemically treated and gamma-irradiated platelet concentrates during storage.
Transfusion 2006;46(5):800-10.
2005: Bruserud Oystein; Tronstad Karl Johan; Berge Rolf
In vitro culture of human osteosarcoma cell lines: a comparison of functional characteristics for cell lines cultured in medium without and with fetal calf serum.
Journal of cancer research and clinical oncology 2005;131(6):377-84.
2005: McCormack E; Bruserud O; Gjertsen B T
Animal models of acute myelogenous leukaemia - development, application and future perspectives.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(5):687-706.
2005: Oyan Anne Margrete; Bø Trond Hellem; Jonassen Inge; Ulvestad Elling; Gjertsen Bjørn Tore; Kalland Karl-Henning; Bruserud Oystein
CD34 expression in native human acute myelogenous leukemia blasts: differences in CD34 membrane molecule expression are associated with different gene expression profiles.
Cytometry. Part B, Clinical cytometry 2005;64(1):18-27.
2005: Abrahamsen J F; Stamnesfet S; Liseth K; Hervig T; Bruserud O
Large-volume leukapheresis yields more viable CD34+ cells and colony-forming units than normal-volume leukapheresis, especially in patients who mobilize low numbers of CD34+ cells.
Transfusion 2005;45(2):248-53.
2005: Ryningen Anita; Wergeland Line; Glenjen Nils; Gjertsen Bjørn Tore; Bruserud Oystein
In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8.
Leukemia research 2005;29(2):185-96.
2004: Abrahamsen J F; Wentzel-Larsen T; Bruserud O
Autologous transplantation: the viable transplanted CD34+ cell dose measured post-thaw does not predict engraftment kinetics better than the total CD34+ cell dose measured pre-freeze in patients that receive more than 2x10(6) CD34+ cells/kg.
Cytotherapy 2004;6(4):356-62.
2003: Bakken A M; Bruserud O; Abrahamsen J F
No differences in colony formation of peripheral blood stem cells frozen with 5% or 10% dimethyl sulfoxide.
Journal of hematotherapy & stem cell research 2003;12(3):351-8.
2003: Bruserud Oystein; Ulvestad Elling
Human acute lymphoblastic leukemia (ALL) blasts as accessory cells during T-cell activation: differences between patients in costimulatory capacity affect proliferative responsiveness and cytokine release by activated T cells.
Cancer immunology, immunotherapy : CII 2003;52(4):215-25.
2002: Hovland Randi; Gjertsen Bjørn Tore; Bruserud Oystein
Acute myelogenous leukemia with internal tandem duplication of the Flt3 gene appearing or altering at the time of relapse: a report of two cases.
Leukemia & lymphoma 2002;43(10):2027-9.
2001: Bruserud O
Effects of azoles on human acute myelogenous leukemia blasts and T lymphocytes derived from acute leukemia patients with chemotherapy-induced cytopenia.
International immunopharmacology 2001;1(12):2183-95.
2001: Foss B; Ulvestad E; Bruserud O
Platelet-derived growth factor (PDGF) in human acute myelogenous leukemia: PDGF receptor expression, endogenous PDGF release and responsiveness to exogenous PDGF isoforms by in vitro cultured acute myelogenous leukemia blasts.
European journal of haematology 2001;66(6):365-76.
2001: Bruserud O; Foss B; Petersen H
Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
European cytokine network 2001;12(2):231-8.
2001: Foss B; Mentzoni L; Bruserud O
Effects of vascular endothelial growth factor on acute myelogenous leukemia blasts.
Journal of hematotherapy & stem cell research 2001;10(1):81-93.
2001: Bruserud O; Gjertsen B T; Foss B; Huang T S
New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of aml cells--the present use in experimental studies and the possible importance for future therapeutic approaches.
Stem cells (Dayton, Ohio) 2001;19(1):1-11.
2000: Bruserud O; Gjertsen B T; von Volkman H L
In vitro culture of human acute myelogenous leukemia (AML) cells in serum-free media: studies of native AML blasts and AML cell lines.
Journal of hematotherapy & stem cell research 2000;9(6):923-32.
2000: Bruserud O; Ulvestad E
Acute myelogenous leukemia blasts as accessory cells during in vitro T lymphocyte activation.
Cellular immunology 2000;206(1):36-50.
2000: Bruserud O; Ulvestad E
Cytokine responsiveness of mitogen-activated T cells derived from acute leukemia patients with chemotherapy-induced leukopenia.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2000;20(11):947-54.
2000: Bruserud O; Ulvestad E
Soluble Fas/Apo-1 (CD95) levels during T cell activation in the presence of acute myelogenous leukemia accessory cells; contributions from local release and variations in systemic levels.
Cancer immunology, immunotherapy : CII 2000;49(7):377-87.
2000: Bruserud O; Foss B; Abrahamsen J F; Gjertsen B T; Ernst P
Autologous stem cell transplantation as post-remission therapy in adult acute myelogenous leukemia: does platelet contamination of peripheral blood mobilized stem cell grafts influence the risk of leukemia relapse?
Journal of hematotherapy & stem cell research 2000;9(4):433-43.
2000: Bruserud O
Effects of imipenem and cilastatin on human T-lymphocytes derived from acute leukemia patients with chemotherapy-induced leucopenia: studies of T-lymphocyte responses in the presence of acute myelogenous leukemia (AML) blast accessory cells.
International journal of immunopharmacology 2000;22(1):69-81.
2000: Bruserud O; von Volkman H L; Ulvestad E
The cellular immune system of patients with acute leukemia and severe chemotherapy-induced leukopenia: characterization of T lymphocyte subsets responsive to IL-16 and IL-17.
Acta haematologica 2000;104(2-3):80-91.
2000: Bruserud O; Tjønnfjord G; Gjertsen B T; Foss B; Ernst P
New strategies in the treatment of acute myelogenous leukemia: mobilization and transplantation of autologous peripheral blood stem cells in adult patients.
Stem cells (Dayton, Ohio) 2000;18(5):343-51.
2000: Bruserud O; Gjertsen B T
New strategies for the treatment of acute myelogenous leukemia: differentiation induction--present use and future possibilities.
Stem cells (Dayton, Ohio) 2000;18(3):157-65.
1999: Bassøe C F; Halstensen A; Bruserud O
Functional differentiation of acute myeloid leukaemia blast cells.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 1999;107(11):1023-33.
1999: Bruserud O; Ulvestad E
Effects of gamma-irradiation on acute myelogenous leukemia blasts: in vitro studies of proliferation, constitutive cytokine secretion, and accessory cell function during T cell activation.
Journal of hematotherapy & stem cell research 1999;8(4):431-41.
1999: Bruserud O
Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1999;13(8):1175-87.
1999: Frostad S; Bruserud O
In vitro effects of insulin-like growth factor-1 (IGF-1) on proliferation and constitutive cytokine secretion by acute myelogenous leukemia blasts.
European journal of haematology 1999;62(3):191-8.
1999: Bruserud O; Frostad S; Foss B
In vitro culture of acute myelogenous leukemia blasts: a comparison of four different culture media.
Journal of hematotherapy 1999;8(1):63-73.
1999: Bruserud O; Ulvestad E
Expression and release of adhesion molecules by human acute myelogenous leukemia blasts.
Leukemia research 1999;23(2):149-57.
1998: Bruserud O; Foss B
Serum thrombopoietin levels in acute leukemia patients with chemotherapy-induced cytopenia--inverse correlation between serum levels and platelet counts.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(10):1653-4.
1998: Bruserud O
IL-4, IL-10 and IL-13 in acute myelogenous leukemia.
Cytokines, cellular & molecular therapy 1998;4(3):187-98.
1998: Bassøe C F; Bruserud O; Pryme I F; Vedeler A
Ribosomal proteins sustain morphology, function and phenotype in acute myeloid leukemia blasts.
Leukemia research 1998;22(4):329-39.
1998: Bruserud O; Ulvestad E; Berentsen S; Bergheim J; Nesthus I
T-lymphocyte functions in acute leukaemia patients with severe chemotherapy-induced cytopenia: characterization of clonogenic T-cell proliferation.
Scandinavian journal of immunology 1998;47(1):54-62.
1998: Frostad S; Bjerknes R; Abrahamsen J F; Olweus J; Bruserud O
Insulin-like growth factor-1 (IGF-1) has a costimulatory effect on proliferation of committed progenitors derived from human umbilical cord CD34+ cells.
Stem cells (Dayton, Ohio) 1998;16(5):334-42.
1997: Bruserud O; Ulvestad E; Halstensen A; Berentsen S; Bergheim J; Nesthus I
Interleukin 4 responses in acute leukaemia patients with severe chemotherapy-induced leucopenia.
European journal of haematology 1997;59(5):269-76.
1996: Bruserud O; Mentzoni L; Foss B; Bergheim J; Berentsen S; Nesthus I
Human T lymphocyte activation in the presence of acute myelogenous leukaemia blasts: studies of allostimulated interferon-gamma secretion.
Cancer immunology, immunotherapy : CII 1996;43(5):275-82.
1996: Bruserud O
Effects of interleukin-13 on cytokine secretion by human acute myelogenous leukemia blasts.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(9):1497-1503.
1996: Bruserud O; Aasen I; Akselsen P E; Bergheim J; Rasmussen G; Nesthus I
Interleukin 1 receptor antagonist (IL1RA) in acute leukaemia: IL1RA is both secreted spontaneously by myelogenous leukaemia blasts and is a part of the acute phase reaction in patients with chemotherapy-induced leucopenia.
European journal of haematology 1996;57(1):87-95.
1996: Bruserud O; Pawelec G
Human T lymphocyte activation in the presence of acute myelogenous leukaemia blasts; studies of normal polyclonal T cells and T lymphocyte clones derived early after allogenic bone marrow transplantation.
Cancer immunology, immunotherapy : CII 1996;42(3):133-40.
1996: Bruserud O
Effects of endogenous interleukin 1 on blast cells derived from acute myelogenous leukemia patients.
Leukemia research 1996;20(1):65-73.
1996: Bruserud O; Mentzoni L; Bühring H J; Pawelec G
Effects of hematopoietic growth factors on interleukin 6 secretion by blast cells derived from acute myelogenous leukemia patients.
Acta haematologica 1996;96(3):155-61.
1995: Bruserud O; Tore Gjertsen B; Brustugun O T; Bassøe C F; Nesthus I; Espen Akselsen P; Bühring H J; Pawelec G
Effects of interleukin 10 on blast cells derived from patients with acute myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(11):1910-20.
1995: Bruserud O; Akselen P E; Bergheim J; Nesthus I
Serum concentrations of E-selectin, P-selectin, ICAM-1 and interleukin 6 in acute leukaemia patients with chemotherapy-induced leucopenia and bacterial infections.
British journal of haematology 1995;91(2):394-402.
1995: Bruserud O; Nesthus I; Bühring H J; Pawelec G
Cytokine modulation of interleukin 1 and tumour necrosis factor-alpha secretion from acute myelogenous leukaemia blast cells in vitro.
Leukemia research 1995;19(1):15-22.
1995: Bruserud O; Nesthus I; Pawelec G
In vitro effect of r-verapamil on acute myelogenous leukemia blast cells: studies of cytokine secretion and cytokine-dependent blast proliferation.
Cancer chemotherapy and pharmacology 1995;37(1-2):70-8.
1994: Bruserud O; Bergheim J; Shammas F V; Nesthus I
Serum concentrations of tumour necrosis factor-alpha during chemotherapy-induced leukopenia in patients with acute leukaemia and bacterial infections.
Leukemia research 1994;18(6):415-21.
1993: Bruserud O; Pawelec G
Effects of dipyridamole and R-verapamil on in vitro proliferation of blast cells from patients with acute myelogenous leukaemia.
Leukemia research 1993;17(6):507-13.
1992: Holen E; Bruserud O; Elsayed S
The effect of disodium cromoglycate on in vitro proliferation of peripheral blood mononuclear cells from allergic and healthy donors.
Scandinavian journal of immunology 1992;36(5):721-31.
1990: Bruserud O
The proliferative response of peripheral blood mononuclear cells to streptokinase. A study of patients receiving a single intravenous infusion of purified streptokinase.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 1990;98(12):1077-84.

Sign-in to see more